Recor Medical Supports New ESC Guidelines for Hypertension Management
Recor Medical Endorses New ESC Guidelines on Hypertension
The European Society of Cardiology (ESC) recently introduced new guidelines aimed at the management of elevated blood pressure and hypertension, enhancing the focus on effective treatment options. Their emphasis on the safety and efficacy of renal denervation stands out, particularly for patients battling uncontrolled hypertension.
Key Highlights of the New Guidelines
During the recent ESC Congress, the latest recommendations were unveiled. Among the critical points, the guidelines advocate for renal denervation (RDN) to be considered a viable treatment method for patients with resistant hypertension or those who are at an increased risk for cardiovascular issues. This is particularly relevant for individuals wishing to explore options beyond traditional medication.
Renal Denervation: A Safe Option
Renal denervation utilizes innovative technology to target overactive sympathetic nerves around the renal arteries. There is increasing evidence that this procedure not only lowers blood pressure but also offers a renewed hope for many patients who have not found success with standard hypertension treatments.
Expert Commentary
Prof. Dr. Michael Böhm, a leading cardiologist, emphasized the significance of these new guidelines in his statements. He noted that the ESC recommendations arose from robust clinical trials, confirming the effectiveness and safety of renal denervation. His commitment lies in actively implementing these guidelines to improve patient care.
Global Impact of Hypertension
Hypertension is a global health crisis, affecting over a billion individuals worldwide. Often labeled the "silent killer," it remains undetected in many patients until severe complications arise. Alarmingly, most patients under treatment fail to achieve adequate blood pressure control, underscoring the need for advanced treatment modalities.
Research and Development at Recor
Recor Medical, through its forward-thinking approach, has developed the Paradise™ Ultrasound Renal Denervation (uRDN) system, marking a breakthrough in hypertension management. This unique system is designed to provide patients with a powerful option to manage their blood pressure effectively.
Positive Clinical Trials
With a solid foundation built from three globally conducted clinical trials involving over 500 patients, the Paradise uRDN system has demonstrated promising outcomes. The results from RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II trials affirm both the efficacy in blood pressure reduction and positive safety profiles.
Commitment to Advancement
With the CE mark obtained in 2012, Recor has actively collaborated with the European cardiology community to integrate uRDN therapy into broader hypertension treatment paradigms. Their ongoing commitment is reflected in their efforts to expand the accessibility of these innovative solutions.
Statements from Leadership
Recor’s President and CEO, Lara Barghout, expressed enthusiasm over the ESC guidelines, recognizing the urgent need to address uncontrolled hypertension globally. Her vision is to revolutionize hypertension management, integrating advanced therapies like the Paradise uRDN system into treatment plans for affected patients.
About Recor Medical, Inc.
Recor Medical operates under Otsuka Medical Devices Co., Ltd. and is dedicated to revolutionizing hypertension management. The company’s innovative work with the Paradise Ultrasound Renal Denervation system plays a pivotal role in tackling hypertension. They are also involved in global registries and post-approval studies aimed at furthering their research and outreach.
About Otsuka Medical Devices
With a firm commitment to developing new therapeutic options, Otsuka Medical Devices Co., Ltd. focuses on pioneering medical devices that address unmet patient needs. The company thrives on innovation, keeping patient safety and effective treatment at the forefront of its mission.
Frequently Asked Questions
What are the new ESC guidelines for hypertension management?
The ESC's new guidelines advocate for renal denervation as an effective treatment for uncontrolled hypertension, emphasizing safety and suitable patient selection.
What is renal denervation (RDN)?
RDN is a medical procedure that targets and denervates overactive nerves surrounding the renal arteries, designed to lower blood pressure in patients unresponsive to medications.
How effective is the Paradise system by Recor Medical?
Clinical trials involving the Paradise uRDN system have shown positive outcomes, indicating significant blood pressure reduction and favorable safety profiles for patients with resistant hypertension.
What commitment does Recor Medical have toward hypertension treatment?
Recor Medical is dedicated to advancing hypertension management, focusing on innovative therapies like the Paradise system to enhance patient outcomes worldwide.
Who can benefit from learning about these new guidelines?
Healthcare professionals, patients with uncontrolled hypertension, and anyone interested in cardiovascular health can benefit from understanding these guidelines and the potential treatment options available.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Lerner Publishing Group Expands Portfolio with New Acquisition
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- Coloplast A/S Share Trading Insights for Board and Executives
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- CenExel Launches Advanced PET Scan Unit for Research
- Object Management Group Launches New Journal of Innovation
- Healthcare Mobility Solutions Market Foresees Major Growth
- Fleet Management Software Market Growth to USD 93.17 Billion
- Affiliated Network Providers and Aurora Health Join Forces
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- 180 Degree Capital Corp. Reports Discount Management Highlights
- Equip Exposition Appoints Chris Meecha as New Show Director
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- Treasure Global Inc Appoints New Directors to Enhance Growth
- Kronos Bio to Showcase Research at Key Medical Conferences
- National Police Association Opposes New Liability Insurance Bill
- Lake City Bank Enhances Warsaw Campus with New Center
- RDE, Inc. Changes Ticker Symbol to GIFT for Growth
- Veterinary Point of Care Diagnostics Market Forecast Growth
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
Recent Articles
- CenExel Launches Advanced PET Scan Unit for Research
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- dxFeed Partners with PriceSquawk to Enhance Trading Experience
- Femasys Highlights Innovation at H.C. Wainwright Conference
- Krispy Krunchy Chicken® Unveils Exciting $4 Meal Deal
- NeuroStar Celebrates Milestone in Suicide Prevention Efforts
- Tennessee Oncology Integrates Nashville Breast Center Team
- Nokia's Strategic Fibre Network Deal with AT&T
- Affimed Names Shawn M. Leland New CEO to Drive Growth
- PharmaCorp Strengthens Position with New Pharmacy Acquisition
- Cognition Therapeutics: Upcoming Investor Conferences Insights
- C4 Therapeutics Welcomes Stephen Fawell, Ph.D. to Leadership
- Cartesian Therapeutics Begins Clinical Trial of Descartes-15
- Patagonia Gold Moves Forward with Calcatreu Project Permit
- Albion Enterprise VCT PLC Reports Strong Interim Results
- HSG Laser Celebrates Four Years of Innovation and Growth
- Calliditas Therapeutics Announces Corporate Actions with Asahi Kasei
- Citi Highlights Dire Challenges Facing China's Economy
- US Dollar Response to ISM Survey and Global Economic Factors
- Kenneth M. Overgaard-Nielsen Joins Computop Management Board
- AliveDx Achieves IVDR-CE Mark for Groundbreaking Celiac Test
- European Shares Steady Awaiting Crucial Economic Data Insights
- GC Biopharma Partners with Hanmi to Advance Fabry Treatment
- Valmet Sets Schedule for Financial Reporting in 2025
- Aker BP Launches Oil Production from Tyrving Field